Text size A - A+

RSS

FOR RELEASE 3/25/2011, Friday

Bausch + Lomb and Technolas Perfect Vision Announce Agreement in Principle to Distribute the First Femtosecond Laser Capable of Performing Both Cataract and Refractive Surgery on One Platform

ROCHESTER, N.Y. — Bausch + Lomb, the global eye health company, and Technolas Perfect Vision GmbH (TPV) today announced an agreement in principle to globally distribute the first femtosecond laser capable of performing both cataract and refractive procedures on one platform. TPV is a leading ophthalmology laser company and was established in 2009 through a joint venture between Bausch + Lomb and 20/10 Perfect Vision AG to develop advanced refractive and cataract technologies. TPV has a full range of expertise in both femtosecond and excimer laser businesses with current innovations focused on laser cataract surgery and the correction of presbyopia.

Under the arrangement, TPV will develop and manufacture its innovative femtosecond cataract and refractive laser system from its state-of-the-art facilities in Munich, Germany, and service the product through its current worldwide service organization. Bausch + Lomb Surgical will leverage its cataract expertise and commercial capabilities to globally distribute TPV's femtosecond laser. Financial terms were not disclosed. TPV will continue to commercialize the refractive portfolio.

Femtosecond laser technology provides greater precision compared to manual techniques in cataract surgery and is better for patients. It allows physicians to create a precise and centered capsulotomy for improved intraocular lens placement and fragments the lens for less invasive removal. Ophthalmologists who perform cataract and refractive procedures will benefit from one platform that supports both clinical applications.

"Femtosecond laser technology for cataract procedures promises to be one of the most significant clinical advances in cataract surgery in 40 years," said Robert E. Grant, chief executive officer and president of Bausch + Lomb Surgical. "The TPV femtosecond laser platform, which uniquely supports refractive and cataract procedures, is a natural complement to our portfolio of cataract products. This is the first of many new technologies we are pursuing focused on enhancing a physician's ability to improve patient outcomes."

"The agreement with Bausch + Lomb capitalizes on the investments TPV has made in advancing the technology and clinical capabilities of femtosecond lasers to meet physician and patient needs by combining cataract and refractive capabilities into one platform. Our strength and proven experience in laser technology, manufacturing and service are a perfect complement to Bausch + Lomb Surgical's global partnership with the ophthalmic community, cataract expertise and marketing and sales abilities," said Dr. Kristian Hohla, chief executive officer of TPV.

Commercialization is expected to begin in the second half of 2011. TPV previously announced that they filed for 510(k) clearance in the United States.

 

About Cataract Surgery

An estimated 20 million aging baby boomers and seniors have cataracts. Over 15 million cataract surgeries are performed worldwide each year. A cataract is a clouding on the normally clear lens in the eye. Cataract surgery is a simple procedure during which the natural lens in the patient's eye is surgically replaced with an intraocular lens.

 

About Bausch + Lomb
Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.